Managing toxicities associated with immune checkpoint inhibitors

被引：5
作者：
Park, Jiyeon Joy [1 ]
Arafath, Syed [2 ]
Kumar, Samir T. [3 ]
Sharma, Roopali [4 ]
Dixit, Deepali [5 ]
机构：
[1] Rutgers State Univ, Ernest Mario Sch Pharm, Rutherford, NJ 08854 USA
[2] Presbyterian Weill Cornell Med Ctr Jama, Oncol Clin Pharm Specialist New York, Jamaica, NY USA
[3] SUNY Downstate Med Ctr, Internal Med Resident, Brooklyn, NY USA
[4] Touro Coll, Sch Pharm, Infect Dis Specialist, New York, NY USA
[5] Robert Wood Johnson Univ Hosp Piscataway, Rutgers & Clin Pharm Specialist Crit Care, Ernest Mario Sch Pharm, Piscataway, NJ USA
来源：
JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2021年 / 34卷 / 06期
关键词：
immune checkpoint inhibitor; toxicity; cancer; immune-related adverse events; adverse reaction; overactivation; DERMATOLOGICAL ADVERSE EVENTS; CANCER-PATIENTS; IPILIMUMAB; MANAGEMENT; NIVOLUMAB; METAANALYSIS; PNEUMONITIS; ANTI-PD-1; BLOCKADE;
D O I：
10.1097/01.JAA.0000735760.65235.3c
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Recent development of immunotherapy has led to remarkable advancement in cancer therapy. Drugs that inhibit the cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed death-1 (PD-1) immune checkpoint pathways have shown improved patient survival. However, by altering the immune response to fight cancer, a new class of adverse reactions has emerged, known as immune-related adverse events. These adverse events are due to overactivation of the immune system in almost any organ of the body, can occur at any point in a patient's treatment course, and may become life-threatening. This article describes how to promptly recognize and manage these toxicities.
引用
收藏
页码：32 / 39
页数：8
相关论文
共 50 条
  • [31] Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors
    Gergely, Tamas G.
    Drobni, Zsofia D.
    Sayour, Nabil V.
    Ferdinandy, Peter
    Varga, Zoltan V.
    BASIC RESEARCH IN CARDIOLOGY, 2025, 120 (01) : 187 - 205
  • [32] Toxicities associated with checkpoint inhibitors-an overview
    Spiers, Laura
    Coupe, Nicholas
    Payne, Miranda
    RHEUMATOLOGY, 2019, 58 : 7 - 16
  • [33] Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system
    Chen, Chen
    Wu, Bin
    Zhang, ChenYu
    Xu, Ting
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 95
  • [34] Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
    Neilan, Tomas G.
    Rothenberg, Mace L.
    Amiri-Kordestani, Laleh
    Sullivan, Ryan J.
    Steingart, Richard M.
    Gregory, William
    Hariharan, Subramanian
    Hammad, Tarek A.
    Lindenfeld, JoAnn
    Murphy, Martin J.
    Moslehi, Javid J.
    ONCOLOGIST, 2018, 23 (08) : 874 - 878
  • [35] Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer
    Howell, Matthew
    Lee, Rebecca
    Bowyer, Samantha
    Fusi, Alberto
    Lorigan, Paul
    LUNG CANCER, 2015, 88 (02) : 117 - 123
  • [36] Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study
    Le, Thomas K.
    Brown, Isabelle
    Goldberg, Rebecca
    Taylor, Matthew T.
    Deng, Junwen
    Parthasarathy, Varsha
    Bordeaux, Zachary A.
    Alphonse, Martin Prince
    Kwatra, Madan M.
    Naranbhai, Vivek
    Gusev, Alexander
    Alhariri, Jihad
    LeBoeuf, Nicole R.
    Reynolds, Kerry L.
    Cappelli, Laura C.
    Naidoo, Jarushka
    Brahmer, Julie R.
    Kang, Sewon
    Semenov, Yevgeniy R.
    Kwatra, Shawn G.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (11) : 2896 - +
  • [37] Immune Checkpoint Inhibitor Toxicities
    Marin-Acevedo, Julian A.
    Chirila, Razvan M.
    Dronca, Roxana S.
    MAYO CLINIC PROCEEDINGS, 2019, 94 (07) : 1321 - 1329
  • [38] Immune Checkpoint Inhibitors and the Heart
    Mocan-Hognogi, Diana Larisa
    Tranca, Sebastian
    Farcas, Anca Daniela
    Mocan-Hognogi, Radu Florin
    Parvu, Andrada Viorica
    Bojan, Anca Simona
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [39] Cutaneous adverse events caused by immune checkpoint inhibitors
    Quach, Henry T.
    Johnson, Douglas B.
    LeBoeuf, Nicole R.
    Zwerner, Jeffrey P.
    Dewan, Anna K.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (04) : 956 - 966
  • [40] Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
    Hradska, Katarina
    Hajek, Roman
    Jelinek, Tomas
    FRONTIERS IN PHARMACOLOGY, 2021, 12
12345